Loading
Led the enasidenib and revumenib trials that brought IDH2 and menin inhibitors to acute leukaemia.
Eytan Stein led the first-in-human trial of the IDH2 inhibitor enasidenib, which won approval for relapsed IDH2-mutant AML, and was a lead investigator of AUGMENT-101, the trial establishing the menin inhibitor revumenib for KMT2A-rearranged and NPM1-mutant acute leukaemia. He heads the leukaemia service at MSKCC and directs early-phase leukaemia drug development.
Shares AUGMENT-101, AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Revumenib, Menin and the tags aml, menin.
Shares AUGMENT-101, AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Revumenib, Acute myeloid leukaemia.
Shares IDH1 / IDH2, Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome, Memorial Sloan Kettering Cancer Center and the tag idh.
Shares AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Revumenib, Menin, Acute myeloid leukaemia.
Shares IDH1 / IDH2, Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome, Acute myeloid leukaemia and the tag aml.
Shares AUGMENT-101, Revumenib, Menin, IDH1 / IDH2.
Shares Blood, Acute myeloid leukaemia and the tag aml.
Shares AUGMENT-101, AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Revumenib, Menin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/